Arcus Biosciences, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Arcus Biosciences, Inc. (RCUS) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$4.15 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2024-02-21
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2023-09-30 was -$0.94.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2023-06-30 was -$1.04.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2023-03-31 was -$1.09.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2022-09-30 was -$0.90.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$4.15.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$3.71, a 622.54% decline from fiscal 2021.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for fiscal 2021 was $0.71.
- Arcus Biosciences, Inc. income (loss) from continuing operations, per diluted share for fiscal 2020 was -$2.24.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$4.15 10-K · filed 2024-02-21 | |||
| 2023-09-30 | -$0.94 10-Q · filed 2023-11-07 | -$3.07 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | -$1.04 10-Q · filed 2023-08-07 | -$2.13 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | -$1.09 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$3.71 10-K · filed 2024-02-21 | |||
| 2022-09-30 | -$0.90 10-Q · filed 2023-11-07 | -$2.78 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$0.93 10-Q · filed 2023-08-07 | -$1.88 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$0.96 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.71 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$1.11 10-Q · filed 2022-11-02 | -$3.28 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | -$0.82 10-K · filed 2021-02-25 | -$2.24 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.03 10-Q · filed 2021-11-08 | -$1.37 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$0.93 10-K · filed 2021-02-25 | |||
| 2020-03-31 | -$0.63 10-K · filed 2021-02-25 | |||
| 2019-12-31 | -$1.93 10-K · filed 2022-02-23 | |||
| 2019-09-30 | -$0.51 10-Q · filed 2020-11-05 | -$1.56 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |